NEWS

Press Releases

Media Coverage

Additional Partnerships

For all media inquiries, please contact media@tempus.com

06/21/2023
Tempus Launches Standalone RNA Sequencing Test, xR

Tempus, a leader in artificial intelligence and precision medicine, today introduces its standalone RNA next-generation sequencing assay, Tempus xR. xR is a whole transcriptome panel for solid tumors, reporting clinically relevant fusions for more than 100 targeted genes, as well as altered splicing for MET Exon 14 and EGFRvIII. Tempus has always understood the importa...
05/01/2023
- Genomic Sequencing
Tempus Receives U.S. FDA Approval for xT CDx, a NGS-Based In Vitro Diagnostic Device

xT CDx is the company’s first Premarket Approval from the FDA Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first Premarket Approval (PMA) application for its companion diagnostic test, xT CDx. xT...
04/03/2023
- Genomic Sequencing
- Life Sciences
Tempus Announces Second Sequencing Collaboration with Lilly to Expand Patient Access to Genomic Testing

Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration sponsored by Eli Lilly and Company designed to expand access to genomic testing for eligible patients who have advanced or metastatic medullary thyroid cancer (MTC) OR advanced or metastatic non-medullary thyroid cancer (non-MTC). This collabora...
06/16/2022
- Data
- Genomic Sequencing
Tempus Announces Research Collaboration with Intermountain Healthcare to Advance Precision Oncology Research

Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Intermountain Healthcare, a Utah-based, nonprofit healthcare system, which leverages genomic testing and data analytics to advance research intended to improve outcomes for cancer patients. Intermountain Healthcare is leveraging Tempus’ solid tumor/normal genomic test, xT, to generate w...
06/09/2022
- Genomic Sequencing
Tempus Announces Sequencing Collaboration with Lilly to Expand Access to Genomic Testing

Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration sponsored by Eli Lilly and Company designed to provide broader access to genomic testing to patients with advanced/metastatic non-small cell lung cancer (NSCLC). Leveraging Tempus tests, this collaboration is intended to help physicians understand th...
06/07/2022
- AI
- Genomic Sequencing
Tempus CE Marks Its Broad-Panel Genomic Sequencing and Algorithmic Diagnostic Tests

Tempus, a leader in artificial intelligence and precision medicine, today announced that it has CE marked a collection of its broad-panel genomic sequencing assays and predictive algorithm laboratory-developed tests. Alongside xT, its primary broad-panel, next-generation sequencing assay, already available on the market, additional Tempus CE marked tests are now...
06/06/2022
Tempus Announces 14 Abstracts Accepted For Presentation at the American Society of Clinical Oncology Annual Meeting 2022

Tempus, a leader in artificial intelligence and precision medicine, today announced abstracts accepted for presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which convenes in Chicago from June 3-7, 2022. Tempus is presenting fourteen abstracts, including one oral presentation, two poster discussions, and eleven poster presentations. “The re...
06/03/2022
- Genomic Sequencing
- Product Launch
Tempus to Launch Largest Clinically Available Liquid Biopsy Panel, xF+

Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of its comprehensive genomic profiling offerings with xF+, a new non-invasive, liquid biopsy panel of 523 genes, focused on pathogenic mutations in cell-free DNA (cfDNA). The test will originally be available on a limited basis alongside xF, Temp...
05/06/2022
- AI
- Genomic Sequencing
Tempus Announces Agreement With the United States Department of Veterans Affairs National Precision Oncology Program To Expand Access to Genomic Testing for Veterans With Cancer

Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year agreement with the United States Department of Veterans Affairs (VA) National Precision Oncology Program (NPOP) designed to expand access to Tempus’ portfolio of next-generation sequencing offerings to support physicians in delivering personalized treatment approaches for their p...
04/08/2022
- AI
- Genomic Sequencing
Tempus Announces Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2022

Tempus, a leader in artificial intelligence and precision medicine, today announced abstracts accepted for presentation at the 2022 American Association for Cancer Research (AACR) Annual Meeting, which convenes in New Orleans from April 8th until April 13th, 2022. The presented research demonstrates how Tempus’ comprehensive genomic sequencing capabilities generate high-quali...

1 2 3 4 5 6 7 8 9